PROM1 and neoplasm: When ATRA was incorporated into lipid-polymer NPs conjugated with CD133 aptamers, increased targeting and therapeutic efficacy against osteosarcoma CSCs was reported over ATRA alone (tumour volume inhibitory rates of 81.1% and 44.3%, respectively) [18].